Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05563246 | A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events | PHASE2 | COMPLETED | 233 | — | — | Nov 24, 2022 | Mar 14, 2024 | Mar 25, 2025 | 42 | United States, Australia +6 |
Least Squares Mean (LS Mean) was calculated using a Mixed Model for Repeated Measures (MMRM): Log (Actual Measurement/Baseline) = Log (Baseline) + Country + Treatment + Time + Treatment\*Time.
LS Mean was calculated using a MMRM: Log (Actual Measurement/Baseline) = Log (Baseline) + Country + Treatment + Time + Treatment\*Time.
| Arm | Type | Description |
|---|---|---|
| 10 mg LY3473329 | EXPERIMENTAL | Participants received 10 milligrams (mg) of LY3473329 administered orally once daily (QD) over a 12-week treatment period. |
| 60 mg LY3473329 | EXPERIMENTAL | Participants received 60 mg of LY3473329 administered orally QD over a 12-week treatment period. |
| 240 mg LY3473329 | EXPERIMENTAL | Participants received 240 mg of LY3473329 administered orally QD over a 12-week treatment period. |
| Placebo | PLACEBO_COMPARATOR | Participants received a matching dose of placebo administered orally QD over a 12-week treatment period. |
| Name | Type | Description |
|---|---|---|
| LY3473329 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Participants must be at least 40 years old * Participants with Lp(a) ≥175 nmol/L at randomization, measured at the central laboratory. * High risk for cardiovascular events defined as documented coronary artery disease (CAD), stroke, or peripheral artery disease or atheroscler...